Phase 2bData readout

IMVT-1402 (FcRn Inhibitor)

Chronic Inflammatory Demyelinating Polyneuropathy

IMVTImmunovant

Expected catalystDecember 31, 2028Company guidance: Dec 31, 2028

Catalyst overview

Event details

Drug or asset: IMVT-1402 (FcRn Inhibitor)
Development stage: Phase 2b
Event type: Data readout
Indication: Chronic Inflammatory Demyelinating Polyneuropathy

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for IMVT-1402 (FcRn Inhibitor) in Chronic Inflammatory Demyelinating Polyneuropathy. The expected timing is based on the latest available company guidance and may change.

Development notes

05/20/26:- CIDP trial remains on track; topline timing remains TBA. 08/06/26:- CIDP topline data expected in 2028.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

IMVT-1402 (FcRn Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

IMVT-1402

IMVT-1402

IMVT-1402

IMVT-1402